Thus, in patients who do not have high-risk CML features (high-risk additional cytogenetic abnormality, mutations in genes such as ASXL1) and in whom TFR is not an aim, it is reasonable to continue the same TKI at the same dose, provided the patient tolerates the drug well, maintains compliance to therapy and is monitored every 3–6 months. Here, ASXL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.